We are proud to work with esteemed cell therapy leaders and appreciate their thoughtful advice as we evolve our science.
Prof Malcolm Brenner MD, PhD
Baylor College of Medicine
Malcolm K Brenner is the Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital and the Fayez Sarofim Distinguished Service Professor at BCM.
Over the past 30 years, Dr Brenner has devoted his career as a physician-scientist to the field of stem cell transplantation through the therapeutic use of T cell immunologic approaches and genetic engineering strategies, particularly in the treatment of cancer.
Prof Jeffrey Miller MD
University of Minnesota
Jeffrey S. Miller, is currently a Professor of Medicine at the University of Minnesota, Division of Hematology, Oncology and Transplantation. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Centerand Roger L. and Lynn C. Headrick Chair in Cancer Therapeutics.
Dr Miller has more than 20 years of experience studying the biology of natural killer (NK) cells and other immune effector cells and their use in clinical immunotherapy with over 200 peer-reviewed publications.
Prof Philippe Moreau MD
University Hospital of Nantes
Philippe Moreau is a Professor of Clinical Hematology and Head of the Translational Research Program in Hematology and Oncology, at the University Hospital of Nantes, France.
He has over 20 years’ experience in clinical hematology and has led many pivotal clinical studies. including with cell therapies. His interests are focused on multiple myeloma (MM) and its treatment with high-dose therapy and novel agents, including cell therapies.
Michael O’Dwyer, MD
University of Galway, Ireland
Michael O’Dwyer is an experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers and has been involved in the clinical drug development of many ground-breaking treatments for Leukemia and Multiple Myeloma.
He is a Professor of Hematology at the University of Galway, Ireland, and Founder, Director and Advisor to ONK Therapeutics. From 2020-2022 Michael was the company’s CSO, where he played a key role in the development of ONK’s optimally engineered NK cell therapy platform.
